NCT05392959View on ClinicalTrials.gov

Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

PHASE4TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin 10 mg Tab

Dapagliflozin 10 mg per day

DRUG

Placebo

Placebo for dapagliflozin film-coated tablets 10 mg

Trial Locations (1)

1000

CHU Saint Pierre, Brussels

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Centre Hospitalier Universitaire Saint Pierre

OTHER